The 32-mg, single intravenous (IV) dose of the anti-nausea drug Zofran (ondansetron hydrochloride) will no longer be marketed because of the potential for serious cardiac risk, according to an updated Safety Communication from FDA.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

FDA updated Safety Communication: Ondansetron (Zofran) 32-mg, single IV dose pulled due to potential for serious cardiac risks

Newsletter